Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coya Therapeutics, Inc.COYA · Entity 6727 | Chief Financial Officer | January 22, 2026 | January 26, 2026 |
| EXICURE, INC.XCUR · Entity 8068 | Chief Financial Officer | March 12, 2020 | March 16, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coya Therapeutics, Inc.
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.73 · Expires 2036-01-22 | Direct | 140,041 |
Reported balance
After 2026-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 140,041 · Balance 140,041 F1: Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
EXICURE, INC.
Report date March 12, 2020 · Filed March 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,248 |
Reported balance
After 2020-03-12 transaction · row 1
1 source rowRow 1 · 2020-03-12 · Purchase · Acquired 18,248 · Balance 18,248 F1: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.3650 to $1.43, inclusive. The reporting person undertakes to provide to Exicure, Inc., any security holder of Exicure, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2030-03-12 | Direct | 230,200 |
Reported balance
After 2020-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-13 · Grant · Acquired 230,200 · Balance 230,200 F2: This option vests in 48 substantially equal monthly installments from March 13, 2020, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.3650 to $1.43, inclusive. The reporting person undertakes to provide to Exicure, Inc., any security holder of Exicure, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: This option vests in 48 substantially equal monthly installments from March 13, 2020, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 26, 2026 08:00 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 140,041 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001193125-26-021729 · ownership.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,041 Underlying: Common Stock, par value $0.0001 per share · 140,041 shares Expires 2036-01-22 F1 · derivative.exercise_date: Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 08:00 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 140,562 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000950170-25-004575 · ownership.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,562 Underlying: Common Stock, par value $0.0001 per share · 140,562 shares Expires 2035-01-09 F1 · derivative.exercise_date: The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date. Read SEC document |
| November 14, 2024 Filed Nov 14, 2024 18:08 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 1,800 | $7.19 | $12,934.44 |
DisclosureSEC source: 0001493152-24-046106 · ownership.xml · nonDerivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:00 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 70,596 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0000950170-24-069551 · ownership.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,596 Underlying: Common Stock · 70,596 shares Expires 2034-06-03 F1 · derivative.exercise_date: Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months, commencing on July 3, 2024. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 20:00 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 81,819 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001493152-24-004815 · ownership.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,819 Underlying: Common Stock · 81,819 shares Expires 2034-01-31 F1 · derivative.exercise_date: The option will vest in 36 equal monthly installments commencing February 29, 2024, subject to continuous service on each vesting date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 16:05 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001493152-23-006389 · ownership.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months commencing on March 27, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 08:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseWarrant to Purchase Common Stock · Derivative | 3,500 | Not disclosed Strike: $7.50 | Not disclosed |
DisclosureSEC source: 0001493152-23-000224 · ownership.xml · derivative · entry 2 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock, par value $0.0001 per share · 3,500 shares Expires 2025-01-03 F1 · price: Reporting Person purchased 7,000 shares of Common Stock and an accompanying warrant to purchase 3,500 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 08:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 7,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-000224 · ownership.xml · nonDerivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 F1 · price: Reporting Person purchased 7,000 shares of Common Stock and an accompanying warrant to purchase 3,500 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 08:46 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 230,200 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001698530-20-000020 · wf-form4_158436278626721.xml · derivative · entry 2 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,200 Underlying: Common Stock · 230,200 shares Expires 2030-03-12 F2 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments from March 13, 2020, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 08:46 UTC | EXICURE, INC. XCUR · Entity 8068 | PurchaseCommon Stock | 18,248 | $1.40 | $25,591.00 |
DisclosureSEC source: 0001698530-20-000020 · wf-form4_158436278626721.xml · nonDerivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,248 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.3650 to $1.43, inclusive. The reporting person undertakes to provide to Exicure, Inc., any security holder of Exicure, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 16:51 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001698530-19-000010 · wf-form4_155147710326978.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments from February 28, 2019, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 17:31 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001698530-18-000038 · wf-form4_153333187899131.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-08-01 F1 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments from August 2, 2018, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:40 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 12,412 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0000899243-17-022828 · doc4.xml · derivative · entry 3 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,412 Underlying: Common Stock · 12,412 shares Expires 2027-01-04 F1 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · derivative.exercise_price: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · shares: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F2 · price: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F5 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments from December 15, 2016, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. F1 · derivative.underlying_shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · derivative.underlying_shares: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:40 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 19,859 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-17-022828 · doc4.xml · derivative · entry 2 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,859 Underlying: Common Stock · 19,859 shares Expires 2025-04-28 F1 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · derivative.exercise_price: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · shares: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F2 · price: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F4 · derivative.exercise_date: This option vests in 48 substantially equal monthly installments from February 20, 2015, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. F1 · derivative.underlying_shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · derivative.underlying_shares: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 21:40 UTC | EXICURE, INC. XCUR · Entity 8068 | GrantEmployee Stock Option (right to buy) · Derivative | 374,133 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000899243-17-022828 · doc4.xml · derivative · entry 1 SNYDER DAVID S · CIK 0001398625 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,133 Underlying: Common Stock · 374,133 shares Expires 2024-10-02 F1 · derivative.exercise_price: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · derivative.exercise_price: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F1 · shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · shares: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F2 · price: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. F3 · derivative.exercise_date: This option vested 25% on July 11, 2015, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions. F1 · derivative.underlying_shares: Pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of September 26, 2017, by and among the Issuer then known as Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc. and the corporation then known as Exicure, Inc. ("Exicure OpCo"), each outstanding share of Exicure OpCo capital stock (other than shares of Series C Preferred Stock of Exicure OpCo) was converted into 0.49649 shares of the Issuer's common stock (the "Conversion Ratio") and each outstanding share of Series C Preferred Stock of Exicure OpCo was converted into 0.7666652 shares of the Issuer's common stock (the "Series C Conversion Ratio"). F2 · derivative.underlying_shares: Each option to purchase shares of Exicure OpCo outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and was converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercises price for such option adjusted to reflect the Conversion Ratio. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.